Resminostat tolerability, pharmacokinetics and pharmacodynamics in cancer patients (phase I trial)

Trial Profile

Resminostat tolerability, pharmacokinetics and pharmacodynamics in cancer patients (phase I trial)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2013

At a glance

  • Drugs Resminostat (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 18 Sep 2009 Results will be presented at the ECCO - ESMO Cancer Conference on 21 September 2009, according to a 4SC media release.
    • 02 Jun 2009 Results presented at ASCO 2009.
    • 09 Dec 2008 Final evaluation of all data is planned for the first quarter of 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top